Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Non-Viral Drug Delivery Systems Market Expansion Outlook: What Revenue Opportunities Are Ahead?
The non-viral drug delivery systems market size has demonstrated rapid expansion in recent years. It is projected to increase from $9.84 billion in 2025 to $11.26 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 14.4%. Historically, this growth can be ascribed to factors such as a reliance on viral delivery methods, limited awareness surrounding non-viral techniques, the progression of emerging biologics development, the establishment of initial regulatory frameworks for drug delivery, and an early academic research focus on nanoparticles.
The non-viral drug delivery systems market size is projected to experience rapid expansion over the next few years, reaching $19.07 billion in 2030 with a compound annual growth rate (CAGR) of 14.1%. This growth during the forecast period is driven by advancements in polymer-based carriers, the rise of RNA and DNA therapeutics, increasing investment in personalized medicine, the expansion of contract development and manufacturing organizations (CDMOs), and growing collaborations between pharmaceutical companies and academic institutions. Noteworthy trends for the forecast period include the increasing adoption of non-viral delivery platforms for targeted therapies, greater use of nanoparticles and liposome-based carriers, a focus on reducing immune response and enhancing safety, continued growth in personalized medicine and targeted therapeutics, and the broadening of CDMOs and academic research collaborations.
Get A Free Sample Report With In-Depth Market Insights:
Non-Viral Drug Delivery Systems Market Demand Drivers: What’s Powering Industry Growth?
The escalating need for personalized medicines is anticipated to boost the expansion of the non-viral drug delivery systems market in the future. This medical strategy customizes treatments based on a person’s genetics, way of life, and surroundings. The rising popularity of personalized medicine stems from its ability to provide more potent therapies by addressing the distinct disease origins in individual patients. Non-viral systems support personalized medicine through the secure delivery of medications or genes to cells, thereby minimizing associated risks and enhancing the accuracy of treatment. An illustration of this trend is observed in February 2024, when the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized therapies for patients with rare diseases in 2023, a significant rise from 6 approvals in 2022. Consequently, the growing requirement for personalized medicines is a key factor propelling the expansion of the non-viral drug delivery systems market.
Non-Viral Drug Delivery Systems Market Segments: Where Is Growth Concentrated?
The non-viral drug delivery systems market covered in this report is segmented –
1) By Type Of Molecule Delivered: Biologics, Small Molecules
2) By Type Of Biologics Delivered: Ribonucleic Acid (RNA), Deoxyribonucleic Acid (DNA), Proteins or Peptides, Antibodies
3) By End User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Development And Manufacturing Organizations (CDMOs), Hospitals And Clinics
Subsegments:
1) By Biologics: Peptides, Proteins, Monoclonal Antibodies, RNA-based Therapeutics, DNA-based Therapies
2) By Small Molecules: Chemotherapeutics, Anti-inflammatories, Antivirals, Antibiotics, Hormonal Drugs
Non-Viral Drug Delivery Systems Market Innovation Trends: What Developments Are Reshaping The Industry?
Companies operating in the non-viral drug delivery system market are increasingly focusing on advanced technologies, such as pre-optimized ionizable lipid mix systems, to streamline the process of developing and delivering RNA-based therapeutics. This formulation technology enables the efficient encapsulation of RNA molecules into lipid nanoparticles, thereby ensuring high stability, payload protection, and targeted delivery for various gene-based drug applications. For instance, in September 2024, Cytiva, a US-based biotechnology company, launched an RNA delivery LNP kit designed to be compatible with its NanoAssemblr Ignite and Ignite+ platforms. This particular system features a ready-to-use ionizable lipid mix, which allows for rapid screening of RNA payloads and effective delivery validation, particularly crucial in the development of infectious disease vaccines. Furthermore, it integrates smoothly with automated microfluidic platforms, supports scalable manufacturing using GMP-grade components, and includes comprehensive protocols and proof-of-concept data to guide users from the early stages of discovery through to clinical evaluation.
Non-Viral Drug Delivery Systems Market Key Participants And Competitive Landscape
Major companies operating in the non-viral drug delivery systems market are Evonik Industries AG, Cytiva, Arcturus Therapeutics Holdings Inc., CureVac N.V., PolyPid Ltd, Ethris GmbH, Entos Pharmaceuticals Inc., Liquidia Technologies Inc., ReCode Therapeutics Inc., Enable Injections Inc., GenEdit Inc., N4 Pharma Plc, Hopewell Therapeutics Inc., Tiba Biotech LLC, Vesigen Therapeutics Inc., Carmine Therapeutics Inc., Evox Therapeutics Ltd, InnoCore Pharmaceuticals BV, Nanomerics Ltd, DelSiTech Ltd, Curapath Inc.
View The Full Non-Viral Drug Delivery Systems Market Report:
Non-Viral Drug Delivery Systems Market Regional Analysis And Top Geography
North America was the largest region in the non-viral drug delivery systems market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-viral drug delivery systems market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
